Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Dosing Plan to Initiate Clinical Studies in at Least Two Autoimmune Diseases in the Second Half of This Year Aurinia to Host Conference Call Today, June 30, at 8:30 a.m. ET

The release as fetched from its publisher. auriniapharma.com ↗